| Literature DB >> 24282373 |
Abstract
Achalasia is a motility disorder of the esophagus, characterized by aperistalsis of the esophageal body and incomplete relaxation of the lower esophageal sphincter (LES). Treatment of achalasia is currently aimed at decreasing the resting pressure in the LES. Peroral endoscopic myotomy (POEM) is an emerging novel endoscopic procedure for the treatment of achalasia with initial data suggesting an acceptable safety profile, excellent short-term symptom resolution, low incidence of postprocedural gastroesophageal reflux (GER), and improvement in manometric outcomes. Further prospective randomized trials are required to evaluate the long-term effectiveness of this promising technique compared to other treatment modalities for achalasia. In this review we outline the technical aspects of POEM, summarize the available data on safety and outcomes, and suggest future directions for further advancement of this minimally invasive approach for the treatment of achalasia.Entities:
Year: 2013 PMID: 24282373 PMCID: PMC3825053 DOI: 10.1155/2013/389596
Source DB: PubMed Journal: Diagn Ther Endosc ISSN: 1026-714X
Clinical trials evaluating POEM for the management of achalasia.
| Authors | Study design |
Patients | Myotomy | Dysphagia score | Eckardt score |
LES pressure; mean |
GERD | Follow-up; mean (range) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; mean | Post-POEM; mean ( | Baseline; mean | Post-POEM; mean ( | Baseline | Post-POEM | ||||||
| Inoue et al. [ | Single-center | 17 | 8.1 (3–15) | 10 | 1.3 | N/A | N/A | 52.4 | 19.8 | N/A | 5 (1–16) months |
| Swanström et al. [ | Single-center | 5 | 10 (10–13) | N/A | 0 or 1 | N/A | N/A | 36.5 | N/A | N/A | 2 weeks |
| von Renteln et al. [ | Single-center | 16 | 12 (8–17) | N/A | N/A | N/A | ≤3 (15, 94%) | 27.2 | 11.8 | None | 3 months |
| Costamagna et al. [ | Single-center | 11 | 10.2 ± 2.8 | N/A | N/A | 7.1 | 1.1 (11, 100%) | 45.1 | 16.9 | None | 3 months |
| Chiu et al. [ | Single-center | 16 | 10.8 | 2 | 0 | 5.5 | 0 | 43.6 ± 24.4 | 29.8 ± 22 | 1/16 | 176.5 (98–230) days |
| Hungness et al. [ | Single-center | 18 | 9 (6–14) | N/A | N/A | 7 | 1 | 19 (7–51) | 9 (0–23) | 4/18 (22%) based on GerdQ score ≥7 | 6 (1–18) months |
| Zhou et al. [ | Single-center | 12 | 10.1 (8–13) | N/A | N/A | ≤3 | 29.4 | 13.5 | 1/12 (8.3%) | 10.4 (5–14) months | |
| Verlaan et al. [ | Single-center | 10 | N/A | N/A | N/A | 8 | 1 | 20.5 | 6.8 | 3/10 (30%) | 3 months |
| Minami et al. [ | Single-center | 28 | 14.4 (10–18) | N/A | N/A | 6.7 | 0.7 | 71.2 | 21.0 | 6/28 (21.4%) | 16 (3–28) months |
| Lee et al. [ | Single-center prospective | 13 | 8.5 (6–13) | N/A | N/A | 6.4 | 0.4 | 30.3 | 15.3 | N/A | 6.9 (1–14) months |
| Von Renteln et al. [ | Multicenter prospective | 70 | 13 (5–13) | N/A | N/A | ≤3 | 27.6 | 8.9 | 37% | 10.1 (3–12) months | |
N/A: not available.
Adverse events associated with POEM.
| Authors | Patients ( | Adverse events*, | Additional treatment |
|---|---|---|---|
| Inoue et al. [ | 17 | 1 pneumoperitoneum | Veress needle |
|
| |||
| Swanström et al. [ | 5 | 2 small perforations in gastric cardia | Endoscopic clips |
|
| |||
| von Renteln et al. [ | 16 | 6 minor cutaneous emphysema | Veress needle |
|
| |||
| Costamagna et al. [ | 11 | 2 small perforations at junctional flap | Endoscopic clips |
|
| |||
| Chiu et al. [ | 16 | 1 aspiration pneumonia | Hospital admission and monitoring |
|
| |||
| Hungness et al. [ | 18 | 7 capnoperitoneum | Veress needle |
|
| |||
| Ren et al. [ | 119 | 66 subcutaneous emphysema | |
|
| |||
| Zhou et al. [ | 12 | 1 small perforation at GEJ, treated with endoscopic clips | Endoscopic clips |
|
| |||
| Verlaan et al. [ | 10 | No complications reported | None |
|
| |||
| Minami et al. [ | 28 | 1 perforation at GEJ, treated with endoscopic clips | Endoscopic clips |
|
| |||
| Lee et al. [ | 13 | No complications reported | None |
|
| |||
| Von Renteln et al. [ | 70 | 3 clip dislocation at mucosal closure | Endoscopic reclipping |
*includes all reported outcomes, including nonclinically significant and asymptomatic adverse events.